A Phase 3 Randomized Clinical Trial to Compare Efficacy and Safety between Combination Therapy and Monotherapy in Elderly Patients with Advanced Gastric Cancer (KCSG ST13-10)
Cancer Research and Treatment · 2023
DOI: 10.4143/crt.2023.333 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Cancer Research and Treatment, 2023. Verfasst von Keun-Wook Lee und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea. Hauptthemen laut MEDLINE: Stomach Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0). Gefördert von: Ministry of Health and Welfare.
Abstract (Originalsprache)
Purpose
This study evaluated whether combination therapy is more effective than monotherapy in elderly patients with metastatic or recurrent gastric cancer (MRGC) as first-line chemotherapy.Materials and Methods Elderly (≥ 70 years) chemo-naïve patients with MRGC were allocated to receive either combination therapy (group A: 5-fluorouracil [5-FU]/oxaliplatin, capecitabine/oxaliplatin, capecitabine/cisplatin, or S-1/cisplatin) or monotherapy (group B: 5-FU, capecitabine, or S-1). In group A, starting doses were 80% of standard doses, and they could be escalated to 100% at the discretion of the investigator. Primary endpoint was to confirm superior overall survival (OS) of combination therapy vs. monotherapy.
Results
After 111 of the planned 238 patients were randomized, enrollment was terminated due to poor accrual. In the full-analysis population (group A [n=53] and group B [n=51]), median OS of combination therapy vs. monotherapy was 11.5 vs. 7.5 months (hazard ratio [HR], 0.86; 95% confidence interval [CI], 0.56 to 1.30; p=0.231). Median progression-free survival (PFS) was 5.6 vs. 3.7 months (HR, 0.53; 95% CI, 0.34 to 0.83; p=0.005). In subgroup analyses, patients aged 70-74 years tended to have superior OS with combination therapy (15.9 vs. 7.2 months, p=0.056). Treatment-related adverse events (TRAEs) occurred more frequently in group A vs. group B. However, among severe TRAEs (≥ grade 3), there were no TRAEs with a frequency difference of > 5%.
Conclusion
Combination therapy was associated with numerically improved OS, although statistically insignificant, and a significant PFS benefit compared with monotherapy. Although combination therapy showed more frequent TRAEs, there was no difference in the frequency of severe TRAEs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, Seongnam, Korea.
- Department of Internal Medicine, Hallym University Sacred Heart Hospital, Anyang, Korea.
- Department of Oncology, Asan Medical Center, Seoul, Korea.
- Department of Internal Medicine, Chungbuk National University Hospital, Chungbuk National University College of Medicine, Cheongju, Korea.
- Department of Internal Medicine, Inje University Busan Paik Hospital, Busan, Korea.
- Division of Oncology and Hematology, Department of Internal Medicine, International St. Mary's Hospital, Catholic Kwandong University College of Medicine, Incheon, Korea.
Förderung
- Ministry of Health and Welfare
Zitieren
APA
Lee, K. W., Zang, D. Y., Ryu, M. H., Han, H. S., Kim, K. H., Kim, M. J., Koh, S. A., Lee, S. S., Koo, D. H., Ko, Y. H., Sohn, B. S., Kim, J. W., Park, J. H., Nam, B. H., & Choi, I. S. (2023). A Phase 3 Randomized Clinical Trial to Compare Efficacy and Safety between Combination Therapy and Monotherapy in Elderly Patients with Advanced Gastric Cancer (KCSG ST13-10). Cancer Research and Treatment. https://doi.org/10.4143/crt.2023.333
Vancouver
Lee KW, Zang DY, Ryu MH, Han HS, Kim KH, Kim MJ, et al. A Phase 3 Randomized Clinical Trial to Compare Efficacy and Safety between Combination Therapy and Monotherapy in Elderly Patients with Advanced Gastric Cancer (KCSG ST13-10). Cancer Research and Treatment. 2023. doi:10.4143/crt.2023.333
BibTeX
@article{Lee2023,
author = {Lee, Keun-Wook and Zang, Dae Young and Ryu, Min-Hee and Han, Hye Sook and Kim, Ki Hyang and Kim, Mi-Jung and Koh, Sung Ae and Lee, Sung Sook and Koo, Dong-Hoe and Ko, Yoon Ho and Sohn, Byeong Seok and Kim, Jin Won and Park, Jin Hyun and Nam, Byung-Ho and Choi, In Sil},
title = {A Phase 3 Randomized Clinical Trial to Compare Efficacy and Safety between Combination Therapy and Monotherapy in Elderly Patients with Advanced Gastric Cancer (KCSG ST13-10)},
journal = {Cancer Research and Treatment},
year = {2023},
doi = {10.4143/crt.2023.333}
}
EUVIMED